-
GEMINI Trial; CAMELOT Trial; INVEST Trial; The Dangers of Vitamin E; FDA Actions.
-
-
From a large-scale bioterror attack to extreme natural disasters, were constantly reminded of looming safety threats and the U.S. infrastructures need to respond. And perhaps no industry has taken the threat more seriously than health care.
-
Promising New Weight Loss Drug?; Treating Shift-Work Disorder; Another Flu Vaccine Shortage?; FDA Actions
-
The International Society for Infectious Diseases (ISID) has provided details on an outbreak of viral hepatitis in India through its ProMED-Mail service.
-
-
Tight glucose control is widely known to lower cardiovascular disease (CVD) risk in Type 2 diabetics. Now, the same can be said for Type 1 diabetics, those who require daily intake of insulin via injection, inhalation or pumps.
-
A host of studies unveiled this summer comparing the drug-eluting stents (DES) of Boston Scientific (Natick, Massachusetts) and the Cordis (Miami Lakes, Florida) unit of Johnson & Johnson (J&J; New Brunswick, New Jersey) have added to the confusion over which device-drug combination is better suited for the treatment of coronary artery disease and the prevention of in-stent restenosis.
-
St. Jude Medical (SJM; St. Paul, Minnesota), already a power in a variety of cardiovascular sectors, has entered the stented tissue valve market with the FDA approval last month of its Biocor and Biocor Supra family of stented tissue valves, its first offerings in that market sector in the U.S.
-
Arrow International (Reading, Pennsylvania) reported entering into a three-year contract with Novation (Irving, Texas), the supply company of VHA and the University HealthSystem Consortium (UHC), for intra-aortic balloon pumps, balloon catheters and accessories.
